Voloridge Investment Management LLC Has $6.33 Million Position in Harrow, Inc. (NASDAQ:HROW)

Voloridge Investment Management LLC decreased its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 12.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 188,592 shares of the company's stock after selling 27,139 shares during the period. Voloridge Investment Management LLC owned about 0.53% of Harrow worth $6,327,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Braidwell LP lifted its position in Harrow by 106.3% in the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after acquiring an additional 467,401 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Harrow by 483.2% during the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company's stock valued at $5,044,000 after buying an additional 124,574 shares during the period. Neuberger Berman Group LLC lifted its stake in shares of Harrow by 128.0% during the fourth quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company's stock valued at $6,728,000 after buying an additional 112,588 shares during the period. Trexquant Investment LP lifted its stake in shares of Harrow by 1,806.8% during the fourth quarter. Trexquant Investment LP now owns 94,500 shares of the company's stock valued at $3,170,000 after buying an additional 89,544 shares during the period. Finally, Deutsche Bank AG lifted its stake in shares of Harrow by 100.9% during the fourth quarter. Deutsche Bank AG now owns 108,064 shares of the company's stock valued at $3,626,000 after buying an additional 54,273 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Performance

Shares of NASDAQ:HROW traded up $1.45 during mid-day trading on Friday, reaching $28.65. 158,585 shares of the company traded hands, compared to its average volume of 461,071. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The firm has a market cap of $1.05 billion, a PE ratio of -30.48 and a beta of 0.41. Harrow, Inc. has a 52 week low of $16.71 and a 52 week high of $59.23. The company's 50 day moving average price is $25.19 and its 200-day moving average price is $30.69.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. On average, equities analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HROW shares. HC Wainwright lifted their price target on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. B. Riley decreased their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.